SERGIO SCHWARTZMAN M.D.
Prescription History 1841225521
Internal Medicine - Rheumatology in New York, NY
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SERGIO SCHWARTZMAN M.D., an active Rheumatology specialist practicing in New York, NY. Our medical registry currently tracks 16 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 345 documented patient claims. Among these therapy options, the most frequently utilized medication is Methylprednisolone, which accounts for 54 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other NY PrescribersVs. NY Avg |
|---|---|---|---|
| Methylprednisolone | 54 | $30.20 | ▲ More than typical |
About Methylprednisolone: Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. Show more ▾ It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders. A PREDNISOLONE derivative with similar anti-inflammatory action. In 2024, this provider wrote 54 Medicare prescriptions for Methylprednisolone, about 1.6 times the volume of the typical New York prescriber of this medication (34.5). Medicare paid an average of $30.20 per fill, versus $7.58 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 88.2 30-Day Fills standardized to 30-day supplies 2,187 Days of Medication total across all patients in 2024 | |||
| Prednisone | 41 | $13.53 | ≈ Typical |
About Prednisone: Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Show more ▾ Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. In 2024, this provider wrote 41 Medicare prescriptions for Prednisone, about 88% of the volume of the typical New York prescriber of this medication (46.6). Medicare paid an average of $13.53 per fill, versus $4.12 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 75.4 30-Day Fills standardized to 30-day supplies 2,158 Days of Medication total across all patients in 2024 | |||
| Taltz AutoinjectorIxekizumab | 39 | $6,851.11▼ below NY avg | ▲ More than typical |
About Taltz Autoinjector: This medication is used to treat plaque psoriasis and certain types of arthritis (psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis). Show more ▾ Ixekizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-17A) that may cause inflammation and swelling. A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS. In 2024, this provider wrote 39 Medicare prescriptions for Taltz Autoinjector, about 2 times the volume of the typical New York prescriber of this medication (20). Medicare paid an average of $6,851.11 per fill, versus $7,483.13 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 39 30-Day Fills standardized to 30-day supplies 1,092 Days of Medication total across all patients in 2024 | |||
| Cosentyx Sensoready (2 Pens)Secukinumab | 23 | $7,754.35▼ below NY avg | ≈ Typical |
About Cosentyx Sensoready (2 Pens): This medication is used to treat plaque psoriasis and certain types of arthritis (such as arthritis of the spine, psoriatic arthritis, axial spondyloarthritis, enthesitis-related arthritis). Show more ▾ It is also used to treat a certain skin disorder (hidradenitis suppurativa). Secukinumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-17A) that may cause inflammation and swelling. A fully human antibody to interleukin-17A for treatment of psoriasis, rheumatoid arthritis, and uveitis. In 2024, this provider wrote 23 Medicare prescriptions for Cosentyx Sensoready (2 Pens), about the same volume as the typical New York prescriber of this medication (20.2). Medicare paid an average of $7,754.35 per fill, versus $8,107.21 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 23 30-Day Fills standardized to 30-day supplies 644 Days of Medication total across all patients in 2024 | |||
| Meloxicam | 23 | $5.59 | ▼ Less than typical |
About Meloxicam: Meloxicam is used to treat arthritis. Show more ▾ It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section. A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS. In 2024, this provider wrote 23 Medicare prescriptions for Meloxicam, about half the volume of the typical New York prescriber of this medication (53.2). Medicare paid an average of $5.59 per fill, versus $3.65 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 52 30-Day Fills standardized to 30-day supplies 1,545 Days of Medication total across all patients in 2024 | |||
| MethotrexateMethotrexate Sodium | 23 | $17.78▼ below NY avg | ▼ Less than typical |
About Methotrexate: Methotrexate is used to treat certain types of cancer (such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma), severe psoriasis that has not responded to other treatments, or rheumatoid arthritis. Show more ▾ It may also be used to treat a certain type of arthritis in children (polyarticular juvenile idiopathic arthritis - pJIA). Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and blocking the immune system from attacking healthy tissue. Early treatment of rheumatoid arthritis with methotrexate helps to reduce further joint damage and to preserve joint function. An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. In 2024, this provider wrote 23 Medicare prescriptions for Methotrexate, about a quarter of the volume of the typical New York prescriber of this medication (96.5). Medicare paid an average of $17.78 per fill, versus $24.43 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 50.6 30-Day Fills standardized to 30-day supplies 1,506 Days of Medication total across all patients in 2024 | |||
| Mycophenolate Mofetil | 19 | $42.27▼ below NY avg | ▼ Less than typical |
About Mycophenolate Mofetil: Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). Show more ▾ It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own. Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. In 2024, this provider wrote 19 Medicare prescriptions for Mycophenolate Mofetil, about 64% of the volume of the typical New York prescriber of this medication (29.8). Medicare paid an average of $42.27 per fill, versus $132.18 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 28 30-Day Fills standardized to 30-day supplies 840 Days of Medication total across all patients in 2024 | |||
| Hydroxychloroquine Sulfate | 18 | $36.49 | ▼ Less than typical |
About Hydroxychloroquine Sulfate: Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. Show more ▾ The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs. This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs). It can reduce skin problems in lupus and prevent swelling/pain in arthritis. Hydroxychloroquine is not recommended for coronavirus infection, also known as COVID-19, unless you are enrolled in a study. Talk to your doctor about the risks and benefits. A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) In 2024, this provider wrote 18 Medicare prescriptions for Hydroxychloroquine Sulfate, about a quarter of the volume of the typical New York prescriber of this medication (85.9). Medicare paid an average of $36.49 per fill, versus $34.33 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 47 30-Day Fills standardized to 30-day supplies 1,410 Days of Medication total across all patients in 2024 | |||
| Orencia ClickjectAbatacept | 16 | $9,187.07 | ▼ Less than typical |
About Orencia Clickject: This medication is used to treat rheumatoid arthritis, a condition in which the body's own defense system (immune system) attacks healthy tissue. Show more ▾ This leads to swelling in the joints, which causes pain and makes it harder to move. Abatacept works by weakening your immune system. This effect helps to slow down joint damage and reduce joint pain and swelling so you can move better. This medication is also used to treat other types of arthritis (such as juvenile idiopathic arthritis, psoriatic arthritis). A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS. In 2024, this provider wrote 16 Medicare prescriptions for Orencia Clickject, about 61% of the volume of the typical New York prescriber of this medication (26.3). Medicare paid an average of $9,187.07 per fill, versus $6,239.17 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 25 30-Day Fills standardized to 30-day supplies 728 Days of Medication total across all patients in 2024 | |||
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $8,420.12 | ≈ Typical |
About Cimzia (2 Pack): This medication is used to reduce pain and swelling due to certain inflammatory conditions (such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis). Show more ▾ Some brands may also be used to treat a certain type of spine condition (axial spondyloarthritis) or a certain bowel condition (Crohn's disease). Certolizumab belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. It works by blocking TNF, a substance made by the body that causes inflammation. A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. In 2024, this provider wrote 15 Medicare prescriptions for Cimzia (2 Pack), about 76% of the volume of the typical New York prescriber of this medication (19.6). Medicare paid an average of $8,420.12 per fill, versus $6,742.40 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 16.8 30-Day Fills standardized to 30-day supplies 476 Days of Medication total across all patients in 2024 | |||
| Febuxostat | 14 | $99.87▼ below NY avg | ▼ Less than typical |
About Febuxostat: Febuxostat is used to lower uric acid levels in people with gout. Show more ▾ Febuxostat works by reducing the amount of uric acid made by the body. An increased uric acid level can cause gout. Because of the risk of very serious heart-related problems and stroke with febuxostat (see also Warning section), febuxostat should be used only after treatment with a medication called allopurinol did not work to lower your uric acid level, caused serious side effects, or is not recommended by your doctor. Febuxostat should be used only if you have symptoms caused by a high blood uric acid level. A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT. In 2024, this provider wrote 14 Medicare prescriptions for Febuxostat, about half the volume of the typical New York prescriber of this medication (24.4). Medicare paid an average of $99.87 per fill, versus $107.36 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 35 30-Day Fills standardized to 30-day supplies 1,050 Days of Medication total across all patients in 2024 | |||
| KevzaraSarilumab | 13 | $4,256.26▼ below NY avg | ▼ Less than typical |
About Kevzara: This medication is used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), or polymyalgia rheumatica (PMR). Show more ▾ Sarilumab belongs to a class of drugs known as monoclonal antibodies. It helps reduce pain and swelling by blocking Interleukin-6, a substance made by the body that causes swelling (inflammation). Antibody against IL-6Ralpha in patients with rheumatoid arthritis. In 2024, this provider wrote 13 Medicare prescriptions for Kevzara, about half the volume of the typical New York prescriber of this medication (22.4). Medicare paid an average of $4,256.26 per fill, versus $4,672.95 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 13 30-Day Fills standardized to 30-day supplies 364 Days of Medication total across all patients in 2024 | |||
| NucalaMepolizumab | 13 | $13,024.12 | ▼ Less than typical |
About Nucala: This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Show more ▾ Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed. A humanized monoclonal antibody to IL-5 in cynomolgus monkeys. In 2024, this provider wrote 13 Medicare prescriptions for Nucala, about half the volume of the typical New York prescriber of this medication (24.7). Medicare paid an average of $13,024.12 per fill, versus $4,428.45 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 14.8 30-Day Fills standardized to 30-day supplies 420 Days of Medication total across all patients in 2024 | |||
| Gabapentin | 12 | $8.00▼ below NY avg | ▼ Less than typical |
About Gabapentin: Gabapentin is used with other medications to prevent and control seizures. Show more ▾ It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug. A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME. In 2024, this provider wrote 12 Medicare prescriptions for Gabapentin, about 15% of the volume of the typical New York prescriber of this medication (82.1). Medicare paid an average of $8.00 per fill, versus $12.77 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the NY average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| KineretAnakinra | 11 | $5,573.88 | ≈ Typical |
About Kineret: Anakinra is used to treat rheumatoid arthritis. Show more ▾ It helps to slow joint damage and reduces the joint pain/swelling so that you can move better. It is also used to treat a certain group of inherited disorders called cryopyrin-associated periodic syndromes (CAPS), including neonatal-onset multisystem inflammatory disease (NOMID). It helps to improve symptoms of NOMID such as fever, rash, joint pain, vomiting, and headache. Anakinra may also be used to treat another condition called Deficiency of Interleukin-1 Receptor Antagonist (DIRA), a condition where your body does not produce the natural protein interleukin-1 receptor antagonist. Anakinra is a man-made form of a natural protein (interleukin-1 receptor antagonist) made by the body. It helps to block the effects of another protein (interleukin-1) which can cause symptoms such as joint pain/swelling/stiffness. The FDA is allowing the emergency use of anakinra to treat coronavirus disease (COVID-19) in hospitalized patients with pneumonia and who also need supplemental oxygen. If anakinra is used to treat coronavirus disease, more information about the drug is available from the patient information sheet provided by your health care professional. A ligand that binds to but fails to activate the INTERLEUKIN 1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA. In 2024, this provider wrote 11 Medicare prescriptions for Kineret, about 78% of the volume of the typical New York prescriber of this medication (14.1). Medicare paid an average of $5,573.88 per fill, versus $4,719.65 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 11 30-Day Fills standardized to 30-day supplies 308 Days of Medication total across all patients in 2024 | |||
| Skyrizi PenRisankizumab-Rzaa | 11 | $20,689.38 | ▼ Less than typical |
About Skyrizi Pen: This medication is used to treat plaque psoriasis and psoriatic arthritis. Show more ▾ It is also used to treat certain bowel diseases (Crohn's disease, ulcerative colitis). Risankizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling. A fully human IgG1 mAb selective for IL-23A; for treatment of moderate-to-severe psoriasis. In 2024, this provider wrote 11 Medicare prescriptions for Skyrizi Pen, about half the volume of the typical New York prescriber of this medication (19.7). Medicare paid an average of $20,689.38 per fill, versus $20,275.71 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average NY prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 27.2 30-Day Fills standardized to 30-day supplies 812 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for SERGIO SCHWARTZMAN M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Rheumatology prescribing approach at this New York, NY practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among NY prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
